Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype (Q39320394)

11 September 2017

1 reference

title

Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype (English)

1 reference

11 September 2017

1 reference

3

Wolfgang Koenig

1 reference

11 September 2017

Veronika Sanin

1

1 reference

11 September 2017

Vanessa Pfetsch

series ordinal

2

1 reference

11 September 2017

publication date

1 July 2017

1 reference

Current cardiology reports

11 September 2017

published in

1 reference

11 September 2017

volume

19

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

61

1 reference

Update on the molecular biology of dyslipidemias

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Mendelian randomization of blood lipids for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

A century of cholesterol and coronaries: from plaques to genes to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Molecular medicine. The cholesterol quartet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Cholesterol, the central lipid of mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

PCSK9: a convertase that coordinates LDL catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Dysfunctional HDL and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Genetic variants associated with Lp(a) lipoprotein level and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Common variants associated with plasma triglycerides and risk for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Remnant cholesterol as a causal risk factor for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

The Genetics of Dyslipidemia--When Less Is More

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Interpretation of the evidence for the efficacy and safety of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Statins for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

A systematic review and meta-analysis on the therapeutic equivalence of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Beneficial cardiovascular pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Pleiotropic effects of statins. - Basic research and clinical perspectives -.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Inactivating mutations in NPC1L1 and protection from coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Mechanism of action of niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Targeting ApoC-III to Reduce Coronary Disease Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

HDL cholesterol efflux capacity and incident cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Genetic and environmental influences on serum lipid levels in twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Mediterranean Diet for Primary Prevention of Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-017-0869-3

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

21 January 2018

1 reference

12 December 2020

'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias

1 reference

12 December 2020

Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial

1 reference

12 December 2020

Polygenic familial hypercholesterolaemia: does it matter?

1 reference

12 December 2020

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators

1 reference

12 December 2020

NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.

1 reference

12 December 2020

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Mediterranean diet for primary prevention of cardiovascular disease

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Familial hypercholesterolaemia

1 reference

12 December 2020

10.1007/S11886-017-0869-3

Identifiers

DOI

1 reference

release_mqgktz2n75hwvaqlu5mlcx3b3y

11 September 2017

Fatcat ID

0 references

1 reference